Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 27Unknown 4Terminated 3Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 17Carcinoma, Hepatocellular 5Recurrence 4Neoplasms, Plasma Cell 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Liver Neoplasms 3Sarcoma 2NSCLC 2Lymphoma, Large B-Cell, Diffuse 2Esophageal Neoplasms 2Waldenstrom Macroglobulinemia 1Stomach Neoplasms 1Pathologic Complete Response 1Osteosarcoma 1Neoplasms, Second Primary 1Neoplasms 1Melanoma 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Large Granular Lymphocytic 1Leiomyosarcoma 1Kidney Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1Immunoblastic Lymphadenopathy 1Glioblastoma 1Extrapancreatic Neuroendocrine Tumor 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 16Dexamethasone 14Melphalan 12Bortezomib 11Filgrastim 6Peripheral Blood Stem Cell Transplantation 5Lenalidomide 5Thalidomide 4Prednisone 4sargramostim 3fludarabine phosphate 3daratumumab 3Radiotherapy 3Mycophenolic Acid 3Interferon-alpha 3Doxorubicin 3Busulfan 3Antilymphocyte Serum 3pomalidomide 2isatuximab 2fludarabine 2Vincristine 2Methylprednisolone 2Idarubicin 2Cyclosporine 2Carmustine 2plerixafor 1pegfilgrastim 1orantinib 1epoetin beta 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Neoplasms, Plasma Cell × Thalidomide × Clear all
NCT01554852 2018-06-11

Myeloma XI

University of Leeds

Phase 3 Unknown
4,420 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03143036 2018-06-07

Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma

National University Hospital, Singapore

Phase 2 Unknown
100 enrolled
Plasma cell

Recurrence, Neoplasms, Plasma Cell

NCT00028886 2013-09-17

Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Unknown
450 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00438841 2009-03-13

Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Unknown
43 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡